Efficacy of multimodality therapy in advanced renal cell carcinoma

Urology

Volumn 51, Issue 6, 1998, Pages 933-937

  Krishnamurthi, Venkatesh ^a   Novick, Andrew C ^a   Bukowski, Ronald M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; MEDICAL RECORD; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0032100461     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00033-8     Document Type: Article

References (19)

1. Selli C., Hinshaw W.M., Woodard B.H., et al. Stratification of risk factors in renal cell carcinoma. Cancer. 52:1986;899-903.
2. Golimbu M., Joshi P., Sperber A., et al. Renal cell carcinoma survival and prognostic factors . Urology. 27:1986;291-301.
3. Belldegrun A., Koo A.S., Bochner B., et al. Immunotherapy for advanced renal cell cancer the role of radical nephrectomy . Eur Urol. 18:(suppl 2):1990;42-45.
4. Buzaid A.C., Robertone A., Kisala C., et al. Phase II study of interferon-alpha-2a recombinant (Roferon-A) in metastatic renal cell carcinoma. J Clin Oncol. 5:1987;1083-1089.
5. Walther M.M., Alexander R.B., Weiss G.H., et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology. 42:1993;250-257.
6. Bennett R.T., Lerner S.E., Taub H.C., et al. Cytoreductive surgery for stage IV renal cell carcinoma. J Urol. 154:1995;32-34.
7. Rackley R.R., Novick A.C., Klein E.A., et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol. 152:1994;1399-1403.
8. Tanguay S., Swanson D.A., Putnam J.B. Jr. Renal cell carcinoma metastatic to the lung potential benefit in the combination of biological therapy and surgery . J Urol. 156:1996;1586-1589.
9. Fleischmann J.D., Kim B. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol. 145:1991;938-941.
10. Long J.P., Walther M.M., Alexander R.B., et al. The management of isolated renal recurrence of renal cell carcinoma following complete response to interleukin-2 based immunotherapy. J Urol. 150:1993;176-178.
11. Kim B., Louie A.C. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg. 127:1992;1343-1349.
12. Hornack M., Ondrus D., Matoska J., et al. Postchemotherapy surgery in nonseminomatous testicular tumors. Eur Urol. 29:1996;325-330.
13. Gerl A., Clemm C., Schmeller N., et al. Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol. 6:1995;483-488.
14. Sella A., Swanson D.A., Ro J.Y., et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol. 149:1993;19-21.
15. Sherry R.M., Pass H.I., Rosenberg S.A., et al. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer. 69:1992;1850-1855.
16. Tolia B.M., Whitmore W.F. Jr. Solitary metastases from renal cell carcinoma. J Urol. 114:1975;836-838.
17. Cerfolio R.J., Allen M.S., Deschamps C., et al. Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 57:1994;339-344.
18. Li X., Liu J., Park J., et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa-B-specific DNA-binding activity a preliminary report . Cancer Res. 54:1994;5424-5429.
19. Alexander J.P., Kudoh S., Melsop K., et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 53:1993;1380-1387.